These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9471737)

  • 1. [Intravesical immunotherapy with BCG vaccine in superficial carcinoma of the urinary bladder].
    Pacík D; Vít V; Turjanica M
    Rozhl Chir; 1997 Oct; 76(10):482-5. PubMed ID: 9471737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pitfalls in intravesical immunotherapy of superficial carcinoma of the gallbladder with BCG vaccine].
    Pacík D; Vít V; Turjanica M
    Rozhl Chir; 1997 Jan; 76(1):3-5. PubMed ID: 9182342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review.
    Tinazzi E; Ficarra V; Simeoni S; Artibani W; Lunardi C
    Rheumatol Int; 2006 Apr; 26(6):481-8. PubMed ID: 16220289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCG-RIVM: a new BCG preparation for intravesical immunotherapy of superficial bladder cancer.
    Schreinemachers L; Van der Meyden A; Steerenberg P; Feitz W; Groothuis D; De Jong W; Debruyne F
    Chemioterapia; 1987 Jun; 6(2 Suppl):713-6. PubMed ID: 3334665
    [No Abstract]   [Full Text] [Related]  

  • 5. [The intravesical administration of BCG vaccine in treating recurrent superficial bladder cancer].
    Panteleeva ES; Neprina GS; Vatin OE; Kariakin OB; Safiullin KN
    Urol Nefrol (Mosk); 1997; (2):29-32. PubMed ID: 9206879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Granulomatous prostatitis after intravesical BCG immunotherapy of superficial bladder cancer: a case report].
    Sai S; Sakakibara T; Takashi M; Sakata T; Miyake K
    Hinyokika Kiyo; 1990 Aug; 36(8):953-5. PubMed ID: 2239600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder].
    Bercovich E; Deriu M; Manferrari F; Irianni G
    Arch Ital Urol Androl; 1995 Sep; 67(4):257-60. PubMed ID: 7581527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Severe self-limiting hypersensitivity reaction after immunotherapy with intravesical BCG].
    Estelles Piera FJ; Campayo A; Valls Ferrer JM; Lacruz J; Blanes Julia FM; López Aldeguer J; Bonora Tamarit V
    An Med Interna; 1994 Oct; 11(10):503-5. PubMed ID: 7865660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
    Steinbach F; Schuster F
    Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The experience with intravesical BCG-immunotherapy in the management of superficial bladder cancer in the United Kingdom.
    Robinson MR
    Prog Clin Biol Res; 1989; 310():147-51. PubMed ID: 2672013
    [No Abstract]   [Full Text] [Related]  

  • 11. [Preventive treatment of superficial tumors of the bladder using intravesical BCG. Review].
    Patard JJ; Chopin DK
    Ann Urol (Paris); 1993; 27(1):24-30. PubMed ID: 8470876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intravesical BCG vaccine in bladder cancer].
    Beisland HO; Sander S
    Tidsskr Nor Laegeforen; 1989 Jun; 109(17-18):1891-2. PubMed ID: 2749672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactive polyarthritis induced by intravesical BCG therapy for carcinoma of the bladder.
    Xerri B; Chrétien Y; Le Parc JM
    Eur J Med; 1993; 2(8):503-5. PubMed ID: 8258055
    [No Abstract]   [Full Text] [Related]  

  • 14. Intravesical BCG therapy in patients with superficial bladder tumors.
    Steg A; Belas M; Leleu C; Boccon-Gibod L
    Prog Clin Biol Res; 1989; 310():153-60. PubMed ID: 2771990
    [No Abstract]   [Full Text] [Related]  

  • 15. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer.
    Hilton WM; Ercole B; Parekh DJ; Sonpavde G; Ghosh R; Svatek RS
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):949-57. PubMed ID: 21707292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reiter syndrome after intravesical Bacillus Calmette-Guerin (BCG) immunotherapy: a case report].
    Shiba M; Fujii T; Takatera H
    Hinyokika Kiyo; 2003 Oct; 49(10):599-601. PubMed ID: 14655604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes in the activity of natural killer cells in superficial bladder cancer during intravesical BCG therapy].
    Samodai L; Dankó K
    Orv Hetil; 1992 Sep; 133(36):2283-6, 2291-2. PubMed ID: 1408062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic potential of recombinant BCG expressing the antigen S1PT in the intravesical treatment of bladder cancer.
    Andrade PM; Chade DC; Borra RC; Nascimento IP; Villanova FE; Leite LC; Andrade E; Srougi M
    Urol Oncol; 2010; 28(5):520-5. PubMed ID: 19272796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.